European Commission approves Novartis’ Xolair® (omalizumab)
Novartis' Xolair (omalizumab) has been approved by the European Commission as an add-on therapy with intranasal corticosteroids to treat severe chronic rhinosinusitis with nasal polyps.
List view / Grid view
News
Filter the results
Prices of remdesivir and favipiravir being monitored in India, says report
Regulatory bodies in India are tracking the cost of remdesivir and favipiravir amid the COVID-19 pandemic but should consider price caps, a report has suggested.
Trump signs ‘Buy American’ executive order aimed to boost US drug production
President Donald Trump has signed the 'Buy American' executive order, which is meant to reduce drug prices and protect the US from supply chain disruptions.
NICE does not recommend chlormethine gel to treat T-cell lymphoma in draft guidance
NICE has issued draft guidance that does not recommend chlormethine gel for mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL).
Novavax presents positive data from Phase I COVID-19 vaccine trial
A Phase I trial conducted by Novavax to test NVX‑CoV2373, the company’s recombinant COVID-19 vaccine candidate, showed it elicited robust antibody responses.
Tinostamustine granted Orphan Drug Designation by European Commission
Tinostamustine has been granted Orphan Drug Designation by the European Commission to the treatment of T-cell prolymphocytic leukaemia (T-PLL).
Commonly used treatments for chronic pain do not work, says NICE
NICE has said commonly used treatments for chronic primary pain such as paracetamol have little or no evidence that they work and should not be prescribed for the condition.
Interleukin-6 inhibitors improve outcomes for COVID-19 patients in study
Researchers have shown that symptoms in patients experiencing severe COVID-19 improved when given either sarilumab or tocilizumab, interleukin-6 inhibitors.
Medicine suppliers in UK urged to stockpile in preparation for end of Brexit transition period
The UK government has written an open letter to medicine suppliers, outlining how supply can be maintained after the end of the Brexit transition period.
FDA issues warning over subpotent and dangerous hand sanitisers
The FDA has updated its list of hand sanitisers to not use, including those with low levels of ethyl alcohol or isopropyl alcohol or with a dangerous presence of methanol.
UK government reserves Wockhardt production line to fill finish COVID-19 vaccines
The UK government reserved a production line at Wockhardt for 18 months to ensure the rapid fill finish of COVID-19 vaccines.
UK to roll out COVID-19 diagnostic that provides results in under two hours
An initial 450,000 of Oxford Nanopore's LamPORE test will be used by the UK government as COVID-19 diagnostics, which yield results in under two hours.
Moderna initiates Phase III trial of COVID-19 vaccine candidate
The first patients have been dosed in Moderna's Phase III clinical trial of its mRNA vaccine candidate to protect against COVID-19.
FDA approves Epidyolex for treatment of tuberous sclerosis complex-associated seizures
Epidyolex, a cannabidiol oral solution, has been given approval by the FDA to treat seizures associated with tuberous sclerosis complex (TSC).
US invests over $240 million into seven new COVID-19 diagnostic tests
The National Institutes of Health in the US has awarded contracts to seven biomedical companies to develop and manufacture COVID-19 diagnostics.